Oncological Safety and Recurrence in the Surgical Treatment of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma of the Scalp

被引:2
|
作者
Zeller, Johannes [1 ]
Kiefer, Jurij [1 ]
Braig, David [1 ,2 ]
Winninger, Oscar [1 ]
Kraus, Daniel [1 ]
Hagelstein, Salome [1 ]
Eisenhardt, Steffen U. [1 ]
机构
[1] Univ Freiburg, Med Ctr, Med Fac, Dept Plast & Hand Surg, D-79106 Freiburg, Germany
[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Div Hand Plast & Aesthet Surg, D-80336 Munich, Germany
关键词
atypic fibroxanthoma; pleomorphic dermal sarcoma; dermal sarcoma; surgical treatment; RELATIVE WEIGHT; MANAGEMENT; MUTATIONS; FREQUENT; INDEXES; EUROPE;
D O I
10.3390/cancers14122869
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Atypical fibroxanthoma and pleomorphic dermal sarcoma represent two tumors on the spectrum of a rare dermal sarcoma entity. Close clinical presentation and nearly identical histologic features but distinct prognoses make proper treatment strategies challenging. We performed a retrospective analysis of 32 patients with AFX or PDS in the scalp to provide guidance regarding the extent of radical excision to achieve stable oncological outcomes and whether radical tumor resection on the scalps required complex soft-tissue reconstruction. Compared to AFX, PDS shows a more aggressive growth pattern with frequent satellite metastases and distant metastases. These require extensive resections for local control to achieve long-term remission in most PDS patients. Despite the limited elasticity of the scalp, plastic reconstructive procedures can obtain reliable soft tissue reconstruction, even for complete scalp defects. Due to their rarity, managing these tumors requires an interdisciplinary setting in a specialized sarcoma center. Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are two distinct designations for a rare dermal sarcoma entity. These tumors arise predominantly in the sun-damaged skin of elderly patients. Although both AFX and PDS have a similar clinical presentation and nearly identical genetic features, they significantly differ in prognosis. Here we present a retrospective single-center chart review analyzing the outcomes of patients treated for dermal sarcoma. The radicality of the tumor-resection extent and soft-tissue reconstructive options were assessed. Patients between January 2010 and August 2021 were included. We recorded resection margins, tumor recurrence, overall survival, number of operations until complete tumor resection, and reconstructive procedures; any complications were recorded. Furthermore, we analyzed a subgroup of patients with satellite metastases. A total of 32 patients met the inclusion criteria (30 male, 2 female, median age of 77.5 years (interquartile range (IQR) 74-81)). Histopathology revealed AFX in 14 patients and PDS in 18 patients. Margin-free resection was achieved in 31 cases, and 27 patients were remission free over the reported period. The local recurrence rate was 5, and distant metastasis was detected in four cases. Of all the PDS cases, nine presented with satellite metastasis. No AFX had satellite metastases. Due to their rarity, managing these tumors requires an interdisciplinary setting in a specialized sarcoma center.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Case report: Pleomorphic dermal sarcoma and atypical fibroxanthoma. Different entities or a spectrum of the same pathology?
    Kapasi, F.
    Cabral, M.
    Ameerally, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 83 - 83
  • [42] The risk of subsequent skin cancer in patients with atypical fibroxanthoma or pleomorphic dermal sarcoma compared to the general population
    van der Waa, Jose
    van Midden, Dominique
    Mellink, Jan Willem Albert
    Flucke, Uta
    Bonenkamp, Johannes Jozef
    Braam, Petra Manou
    Drissen, Meggie Margaretha Catharina Maria
    Louwman, Marieke
    Amir, Avital Leonie
    Lubeek, Satish Frank Kishore
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (04) : 724 - 727
  • [43] Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma
    Helbig, Doris
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [44] Atypical fibroxanthoma, pleomorphic sarcoma or malignant melanoma? - a case presentation
    Potenberg, J.
    Dombrowski-Luetcke, M.
    Minck, C.
    Reyher-Klein, S.
    Oncology Research and Treatment, 2015, 38 : 255 - 256
  • [45] Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden
    Ak, Melike
    Kahraman, Abdullah
    Arnold, Fabian M.
    Turko, Patrick
    Levesque, Mitchell P.
    Zoche, Martin
    Ramelyte, Egle
    Dummer, Reinhard
    GENES, 2021, 12 (07)
  • [46] Atypical fibroxanthoma and pleomorphic dermal sarcoma - gene expression analysis compared with undifferentiated cutaneous squamous cell carcinoma
    Anders, Iris Marie
    Schimmelpfennig, Carolin
    Wiedemann, Karolin
    Loeffler, Dennis
    Kaempf, Christoph
    Blumert, Conny
    Reiche, Kristin
    Kunz, Manfred
    Anderegg, Ulf
    Simon, Jan-Christoph
    Ziemer, Mirjana
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 (05): : 492 - 492
  • [47] Pleomorphic Dermal Sarcoma Adverse Histologic Features Predict Aggressive Behavior and Allow Distinction From Atypical Fibroxanthoma
    Miller, Keith
    Goodlad, John R.
    Brenn, Thomas
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (09) : 1317 - 1326
  • [48] Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma?
    Ricci, Costantino
    De Leo, Antonio
    Dika, Emi
    Lambertini, Martina
    Veronesi, Giulia
    Corti, Barbara
    ACTA HISTOCHEMICA, 2020, 122 (02)
  • [49] Somatic Mutation Profile of Atypical Fibroxanthoma and Cutaneous Undifferentiated Pleomorphic Sarcoma
    Lim, Young H.
    Zaki, Theodore D.
    Levinsohn, Jonathan L.
    Galan, Anjela
    Choate, Keith A.
    Hanlon, Allison M.
    DERMATOLOGIC SURGERY, 2021, 47 (02) : 290 - 292
  • [50] High intratumoral 5-Hydroxymethylcytosine Levels protect against Recurrence in Patients with atypical Fibroxanthoma and pleomorphic Sarcoma
    Weyer-Fahlbusch, S. S.
    Razeghpour, F.
    Abu Rached, N.
    Becker, J. C.
    Susok, L.
    Gambichler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 : 7 - 7